Targeting Adiponectin in Breast Cancer

Area of Science:

• Metabolic signaling
• Oncology
• Endocrinology

Background:

• Obesity is a significant risk factor for postmenopausal breast cancer.
• Adipokines, particularly adiponectin, play a crucial role in the obesity-cancer relationship.
• Adiponectin is known for its protective effects and is increasingly implicated in cancer regulation.

Purpose of the Study:

• To provide an updated overview of metabolic signaling linking adiponectin and breast cancer.
• To critically summarize therapeutic candidates targeting adiponectin receptors.
• To highlight adiponectin's potential as a biomarker and therapeutic target for breast cancer.

Main Methods:

• Review of existing literature on adiponectin, obesity, and breast cancer.
• Analysis of metabolic signaling pathways involved in adiponectin's function.
• Summary of synthetic small molecules, plant-based proteins, and peptide sequences targeting adiponectin receptors.

Main Results:

• Adiponectin exhibits anti-cancer properties, potentially preventing breast cancer development and progression.
• Several therapeutic agents, including small molecules and peptides, show promise in reactivating adiponectin pathways.
• Genomic advances enable the creation of peptide sequences that mimic adiponectin's function.

Conclusions:

• Adiponectin's anti-cancer activity against breast cancer warrants further exploitation.
• Targeting adiponectin and its receptors represents a viable strategy for breast cancer management.
• Adiponectin should be considered a significant biomarker for breast cancer intervention.